HC Wainwright Forecasts Strong Price Appreciation for Humacyte (NASDAQ:HUMA) Stock

Humacyte (NASDAQ:HUMA) had its price target boosted by equities researchers at HC Wainwright from $6.00 to $12.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 120.99% from the stock’s current price. HC Wainwright also issued estimates for Humacyte’s FY2028 earnings at $0.71 EPS.

A number of other research firms have also weighed in on HUMA. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. Finally, TD Cowen reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Humacyte has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Stock Up 4.0 %

HUMA stock opened at $5.43 on Tuesday. The stock has a fifty day moving average of $5.49 and a 200-day moving average of $6.12. Humacyte has a fifty-two week low of $2.08 and a fifty-two week high of $9.97. The company has a market capitalization of $648.07 million, a price-to-earnings ratio of -4.31 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, equities research analysts predict that Humacyte will post -1.09 earnings per share for the current year.

Insider Buying and Selling at Humacyte

In related news, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the transaction, the chief executive officer now directly owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 277,090 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the transaction, the chief executive officer now directly owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock valued at $6,869,996 in the last 90 days. Corporate insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Humacyte in the 2nd quarter worth approximately $28,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte in the 3rd quarter worth approximately $75,000. Principal Financial Group Inc. purchased a new stake in shares of Humacyte in the 2nd quarter valued at $83,000. Profund Advisors LLC bought a new position in shares of Humacyte during the 2nd quarter valued at $97,000. Finally, XTX Topco Ltd purchased a new position in Humacyte in the 2nd quarter worth $110,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.